Investors Urged to Participate in Class Action Against Regeneron Pharmaceuticals Over Allegations of Securities Fraud

Investor Alert: Class Action Lawsuit Filed Against Regeneron Pharmaceuticals

In a significant legal development, Pomerantz LLP has announced the filing of a class action lawsuit against Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron (NASDAQ: REGN). Investors who have experienced losses on their investments in Regeneron are urged to take action, especially those who acquired securities during the Class Period. The firm is known for its expertise in corporate securities litigation and aims to protect the rights of investors against potential misconduct.

The class action addresses allegations that Regeneron, along with certain officers and directors, may have engaged in securities fraud or other unlawful business practices. Those affected are encouraged to reach out to Pomerantz, either via email or phone. For effective communication, it is advised that investors include their personal details such as mailing addresses and the number of shares they purchased during the significant periods identified by the lawsuit.

Key Dates and Information

Investors have until September 14, 2026, to petition the court for Lead Plaintiff status if they meet the requirements. This is a crucial step that could allow them to represent the class in the ongoing legal proceedings. Copies of the complaint can be accessed through Pomerantz Law's website, ensuring transparency in the proceedings.

Recent events leading to the lawsuit include remarks made by Regeneron during its first quarter earnings call on April 29, 2026. The company disclosed changes to a significant clinical trial, known as the Phase III Fianlimab-Libtayo Study, which raised concerns about the accuracy of its data. As a result, there was a notable decline in Regeneron's stock value, with shares dropping $45.41 on that very day, marking a 6.21% decrease.

Subsequently, on May 15, 2026, Regeneron released a press statement indicating that the Phase III trial results did not meet the expected benchmarks for improvement in progression-free survival, leading to further declines in stock value. On May 16, the stock fell a staggering $68.57, translating to a 9.82% drop and closing at $629.68 per share.

Pomerantz LLP: A Leader in Class Action Litigation

Pomerantz LLP has built a strong reputation as a premier law firm in the fields of corporate, securities, and antitrust class litigation. Established by the esteemed Abraham L. Pomerantz, the firm has a legacy of championing the rights of investors and securing substantial recoveries for victims of securities fraud. With offices spread across key locations including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz continues to uphold its tradition of excellence in legal advocacy.

If you believe you have been impacted by Regeneron’s business practices and wish to explore your legal options, reach out to Danielle Peyton at 646-581-9980 or toll-free at 888.4-POMLAW (ext 7980). Remember, prior results do not guarantee similar outcomes, but taking action now may help safeguard your interests in the turbulent world of investing.

In conclusion, as the timeline unfolds, it is critical for investors to stay informed about developments in this case and to actively participate if eligible. The outcome of this class action could lead to significant ramifications in how corporate governance and transparency are managed in the pharmaceutical industry.